TW200606162A - Pyrazolopyridine derivatives - Google Patents

Pyrazolopyridine derivatives

Info

Publication number: TW200606162A
Authority: TW; Taiwan
Prior art keywords: pyrazolopyridine derivatives; pyrazolopyridine; derivatives; pde; tnf
Prior art date: 2004-07-05

Application number

TW094122527A

Other languages

English (en)

Inventor

Yoshito Abe

Kazuhiko Ohne

Kentaro Sato

Makoto Inoue

Mitsuaki Okumura

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-05

Filing date

2005-07-04

Publication date

2006-02-16

2004-07-05 Priority claimed from AU2004903691A external-priority patent/AU2004903691A0/en

2005-07-04 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2006-02-16 Publication of TW200606162A publication Critical patent/TW200606162A/zh

Links

150000005229 pyrazolopyridines Chemical class 0.000 title 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

TW094122527A 2004-07-05 2005-07-04 Pyrazolopyridine derivatives TW200606162A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AU2004903691A AU2004903691A0 (en)		2004-07-05	Pyrazolopyridine Derivatives

Publications (1)

Publication Number	Publication Date
TW200606162A true TW200606162A (en)	2006-02-16

Family

ID=35431022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094122527A TW200606162A (en)	2004-07-05	2005-07-04	Pyrazolopyridine derivatives

Country Status (13)

Country	Link
US (1)	US7459451B2 (zh)
EP (1)	EP1763528B1 (zh)
JP (1)	JP5092402B2 (zh)
KR (1)	KR20070042164A (zh)
CN (1)	CN1980927A (zh)
AR (1)	AR053306A1 (zh)
AT (1)	ATE415400T1 (zh)
CA (1)	CA2571588A1 (zh)
DE (1)	DE602005011286D1 (zh)
ES (1)	ES2319797T3 (zh)
MX (1)	MXPA06014699A (zh)
TW (1)	TW200606162A (zh)
WO (1)	WO2006004188A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080065704A (ko)	2005-11-09	2008-07-14	콤비네이토릭스, 인코포레이티드	의학적 이상의 치료 방법들, 조성물들, 및 키트들
EP2038279A2 (en)	2006-06-06	2009-03-25	Avigen, Inc.	Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
NZ579645A (en)	2007-03-14	2012-01-12	Ranbaxy Lab Ltd	Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US7536799B2 (en) *	2007-06-07	2009-05-26	Keson Industries	Chalk line apparatus with strategically located chalk fill opening
WO2009062308A1 (en) *	2007-11-16	2009-05-22	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication
EP2070929A1 (en)	2007-12-11	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009109525A1 (en) *	2008-03-03	2009-09-11	Nycomed Gmbh	Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
US20110105510A1 (en) *	2008-06-17	2011-05-05	Hiroshi Ishikawa	Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010016846A1 (en) *	2008-08-08	2010-02-11	Kalypsys, Inc.	Heterocyclic modulators of tgr5 for treatment of disease
FR2951172B1 (fr) *	2009-10-13	2014-09-26	Pf Medicament	Derives pyrazolopyridines en tant qu'agent anticancereux
KR101774035B1 (ko) *	2009-10-30	2017-09-01	얀센 파마슈티카 엔.브이.	이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
WO2011142724A1 (en) *	2010-05-14	2011-11-17	Agency For Science, Technology And Research	Novel antimicrobial compounds and uses thereof
EP2593453B1 (en)	2010-07-15	2014-09-17	Bristol-Myers Squibb Company	Azaindazole compounds
WO2012019954A1 (en)	2010-08-12	2012-02-16	Evotec (Uk) Ltd.	Pyrazolopyridine compounds as pde10a inhibitors
US9266880B2 (en)	2010-11-12	2016-02-23	Bristol-Myers Squibb Company	Substituted azaindazole compounds
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2659763T3 (es)	2011-02-14	2018-03-19	The Regents Of The University Of Michigan	Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
EP2760870B1 (en)	2011-09-27	2016-05-04	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
EP2991647B1 (en)	2013-05-02	2019-04-24	The Regents Of The University Of Michigan	Deuterated amlexanox with improved metabolic stability
WO2015153959A2 (en) *	2014-04-04	2015-10-08	The Regents Of The University Of Michigan	Small molecule inhibitors of mcl-1 and uses thereof
CN104230811B (zh) *	2014-07-30	2016-09-28	斯芬克司药物研发（天津）股份有限公司	一种吡唑吡啶化合物及其制备方法
PE20181348A1 (es) *	2015-10-09	2018-08-22	Abbvie Sarl	PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y METODO DE USO
EP3407974A4 (en)	2016-01-29	2019-08-28	The Regents Of The University Of Michigan	Amlexanox Analogs
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
JOP20190126A1 (ar) *	2016-12-22	2019-05-28	H Lundbeck As	بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
CN110475817A (zh) *	2017-03-28	2019-11-19	嘉吉公司	易水混溶性β-葡聚糖悬浮液
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
PT3723807T (pt)	2017-12-14	2021-11-26	H Lundbeck As	Tratamentos de associação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
CN117447475A (zh)	2017-12-20	2024-01-26	H.隆德贝克有限公司	作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
CN108558876B (zh) *	2018-05-28	2020-08-04	中南大学	吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用
US12486269B2 (en)	2024-02-08	2025-12-02	Aconcagua Bio, Inc.	Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171341A2 (en) *	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4822799A (en) *	1988-01-27	1989-04-18	Sandoz Pharm. Corp.	Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
US5024999A (en) *	1988-04-26	1991-06-18	Nissan Chemical Industries Ltd.	Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP3130342B2 (ja) *	1991-10-04	2001-01-31	日産化学工業株式会社	動脈硬化性血管内膜肥厚抑制薬
US6326379B1 (en) *	1998-09-16	2001-12-04	Bristol-Myers Squibb Co.	Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) *	2000-07-07	2002-01-23	Ono Pharmaceut Co Ltd	ピラゾロピリジン誘導体
JP2004526789A (ja) *	2001-04-25	2004-09-02	アルタナ　ファルマ　アクチエンゲゼルシャフト	新規フタラジノン
WO2004024728A2 (en) *	2002-09-16	2004-03-25	Glaxo Group Limited	Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
MXPA05007462A (es)	2003-01-09	2006-01-27	Astellas Pharma Inc	Derivados de pirrolopiridazina.

2005
- 2005-07-01 WO PCT/JP2005/012618 patent/WO2006004188A1/en not_active Ceased
- 2005-07-01 MX MXPA06014699A patent/MXPA06014699A/es active IP Right Grant
- 2005-07-01 CN CNA2005800225451A patent/CN1980927A/zh active Pending
- 2005-07-01 US US11/171,320 patent/US7459451B2/en not_active Expired - Fee Related
- 2005-07-01 AT AT05757839T patent/ATE415400T1/de not_active IP Right Cessation
- 2005-07-01 ES ES05757839T patent/ES2319797T3/es not_active Expired - Lifetime
- 2005-07-01 CA CA002571588A patent/CA2571588A1/en not_active Abandoned
- 2005-07-01 DE DE602005011286T patent/DE602005011286D1/de not_active Expired - Lifetime
- 2005-07-01 JP JP2006553787A patent/JP5092402B2/ja not_active Expired - Fee Related
- 2005-07-01 EP EP05757839A patent/EP1763528B1/en not_active Expired - Lifetime
- 2005-07-01 KR KR1020077002746A patent/KR20070042164A/ko not_active Withdrawn
- 2005-07-04 TW TW094122527A patent/TW200606162A/zh unknown
- 2005-07-04 AR ARP050102779A patent/AR053306A1/es unknown

Also Published As

Publication number	Publication date
CN1980927A (zh)	2007-06-13
JP2008505056A (ja)	2008-02-21
US20060004003A1 (en)	2006-01-05
AR053306A1 (es)	2007-05-02
EP1763528A1 (en)	2007-03-21
EP1763528B1 (en)	2008-11-26
US7459451B2 (en)	2008-12-02
MXPA06014699A (es)	2007-03-26
DE602005011286D1 (en)	2009-01-08
CA2571588A1 (en)	2006-01-12
KR20070042164A (ko)	2007-04-20
ES2319797T3 (es)	2009-05-12
JP5092402B2 (ja)	2012-12-05
WO2006004188A1 (en)	2006-01-12
ATE415400T1 (de)	2008-12-15

Publication	Publication Date	Title
TW200606162A (en)	2006-02-16	Pyrazolopyridine derivatives
MXPA05007462A (es)	2006-01-27	Derivados de pirrolopiridazina.
WO2005013892A3 (en)	2005-06-16	Hydrolytically-resistant boron-containing therapeutics and methods of use
EA200800564A1 (ru)	2008-08-29	Производные ксантина как селективные агонисты нм74а
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009010059A (es)	2009-10-12	Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
UA98961C2 (uk)	2012-07-10	Похідні піразинону та їх застосування у лікуванні легеневих захворювань
TNSN08283A1 (en)	2009-10-30	Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
GEP20084551B (en)	2008-11-25	4-phenylamino-quinazolin-6-yl-amides
MY161991A (en)	2017-05-31	Proteasome inhibitors
MX2009006706A (es)	2009-07-02	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
IL184898A0 (en)	2007-12-03	Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
UA102251C2 (ru)	2013-06-25	Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MY166653A (en)	2018-07-18	Derivatives of 1-amino-2-cyclobutylethylboronic acid
GEP20084452B (en)	2008-08-10	Sulfonamide derivatives for the treatment of diseases
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
UA104988C2 (uk)	2014-04-10	Похідні піроніндолу та спосіб їх отримання
TW200621262A (en)	2006-07-01	New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2010009022A (es)	2010-09-07	Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
EA200601212A1 (ru)	2006-10-27	Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
JO2682B1 (en)	2013-03-03	Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
TW200738659A (en)	2007-10-16	Novel compounds
TW200724537A (en)	2007-07-01	Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200626553A (en)	2006-08-01	Novel compounds
CO5660287A2 (es)	2006-07-31	Derivados de tetrahidrocarbazol y su uso farmaceutico